Nanotechnology Now







Heifer International

Wikipedia Affiliate Button


DHgate

Home > Press > Dr. Joyce Sutcliffe Joins the NanoBio Team as Vice President of Research

Abstract:
NanoBio(R) Corporation, a biopharmaceutical company focused on developing and commercializing novel products for the prevention and treatment of infectious diseases, today announced the addition of Joyce Sutcliffe, Ph.D., as vice president of research.

Dr. Joyce Sutcliffe Joins the NanoBio Team as Vice President of Research

ANN ARBOR, MI | Posted on October 30th, 2007

Sutcliffe brings 26 years of experience in the discovery and design of new antibiotics, with particular emphasis on understanding and overcoming antibiotic resistance. She joined the NanoBio team from Rib-X Pharmaceuticals, where she served as vice president of biology and chief research scientist.

During her tenure at Rib-X Pharmaceuticals and previously at Pfizer and Abbott, Sutcliffe focused on leveraging knowledge about target-based resistance to help design novel antibiotics that are potent against organisms with antibiotic resistance. She also led teams that evaluated efficacy and pharmacokinetics in animal disease models to ensure safety and compatibility with other drugs.

"Antibiotic resistance drives the need for new treatments against tenacious infectious microorganisms that continue to mutate," said Sutcliffe. "For example the rampant explosion of MRSA (methicillin-resistant Staphylococcus aureus) in the community has led to a need for safe anti- infectives. These bacteria are no longer resistant to just antibiotics but have become multidrug-resistant by adding other resistance mechanisms to their armamentarium.

"NanoBio's deep pipeline of topical anti-infectives and mucosal vaccines is particularly compelling, given the platform technology poses a very low risk of resistance while having broad antimicrobial activity against a wide range of infections," Sutcliffe said.

NanoBio's line of anti-infectives are designed to wage a two-pronged attack against bacteria, viruses, and fungi using safe detergents along with high-energy nanoemulsions to physically disrupt pathogen membranes and lyse microbes, said James Baker, Jr., M.D., founder and CSO of NanoBio Corporation. The absence of a specific metabolic target significantly reduces the likelihood of triggering resistant infections, he added.

"The addition of Dr. Sutcliffe, an internationally recognized anti- infective expert, will enable NanoBio to accelerate the number of product candidates we take into the clinic for preventing and treating a wide range of infections," said Baker.

####

About NanoBio(R) Corporation
NanoBio(R) Corporation is a privately held biopharmaceutical company focused on developing and commercializing anti-infective products and mucosal vaccines derived from its patented NanoStat(TM) technology platform. The company's lead product candidates are treatments for herpes labialis (cold sores), onychomycosis (nail fungus), MRSA and mucosal vaccines for influenza and hepatitis B. The company's headquarters and laboratory facilities are located in Ann Arbor, Mich.

For more information, please click here

Contacts:
NanoBio® Corporation

2311 Green Road, Suite A
Ann Arbor, Michigan 48105
Telephone:734.302.4000
Fax:734.302.9150

Copyright © PR Newswire Association LLC.

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

Nanomedicine

Untangling DNA with a droplet of water, a pipet and a polymer: With the 'rolling droplet technique,' a DNA-injected water droplet rolls like a ball over a platelet, sticking the DNA to the plate surface February 27th, 2015

Graphene shows potential as novel anti-cancer therapeutic strategy: University of Manchester scientists have used graphene to target and neutralise cancer stem cells while not harming other cells February 26th, 2015

Cutting-edge technology optimizes cancer therapy with nanomedicine drug combinations: UCLA bioengineers develop platform that offers personalized approach to treatment February 24th, 2015

Optical nanoantennas set the stage for a NEMS lab-on-a-chip revolution February 24th, 2015

Announcements

Scientific breakthrough in rechargeable batteries: Researchers from Singapore and Québec Team Up to Develop Next-Generation Materials to Power Electronic Devices and Electric Vehicles February 28th, 2015

First detailed microscopy evidence of bacteria at the lower size limit of life: Berkeley Lab research provides comprehensive description of ultra-small bacteria February 28th, 2015

Leti to Offer Updates on Silicon Photonics Successes at OFC in LA February 27th, 2015

Moving molecule writes letters: Caging of molecules allows investigation of equilibrium thermodynamics February 27th, 2015

Appointments/Promotions/New hires/Resignations/Deaths

KIT Increases Commitment in Asia: DAAD Funds Two New Projects: Strategic Partnerships with Chinese Universities and Communi-cation Technologies Network February 22nd, 2015

SouthWest Nanotechnologies CEO Dave Arthur Appointed to the Board of Affiliates of Rice University Professional Science Master’s Program February 13th, 2015

Nexeon Board Changes Announced January 29th, 2015

Rice's Naomi Halas to direct Smalley Institute: Optics pioneer will lead Rice's multidisciplinary science institute January 15th, 2015

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More










ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2015 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE